J Gynecol Oncol.  2024 Mar;35(2):e65. 10.3802/jgo.2024.35.e65.

Evolving standards and future directions for systemic therapies in cervical cancer

• Ang DJM
• Chan JJ

• KMID: 2564887
• DOI: http://doi.org/10.3802/jgo.2024.35.e65

Abstract

Several groundbreaking clinical trials with the potential to transform the management paradigm of both locally advanced and persistent, recurrent, or metastatic cervical cancers have been presented in 2023. This review describes the reported data from INTERLACE and KEYNOTE-A18 in the locally advanced setting, as well as BEATcc, innovaTV 301 and DESTINY-PanTumor02 for advanced disease. The practice implications of their positive results are interpreted in the context of global health considerations, and updated treatment algorithms are proposed. Furthermore, emerging trends in drug development for cervical cancer are discussed. As the routine use of immune checkpoint inhibitors (ICIs) for curative and palliative indications increases in the foreseeable future, patients whose cervical cancers which persist, relapse or progress after prior ICI exposure will represent an area of unmet clinical need and form the key target population for next-generation trials. Future research will help shape oncologists’ approaches in the optimal selection, sequencing and re-treatment or rechallenge of immuno-oncology agents and/or antibody-drug conjugates in women with cervical cancer.

Keyword

Cervical Cancer; Chemoradiotherapy; Immune Checkpoint Inhibitors; Immunoconjugates; Adoptive Immunotherapy